Core Insights - The company is focusing on automation and artificial intelligence to enhance efficiency in revenue cycle functions, with 40% of claims processed without human intervention [1] - The company serves as the largest independent provider of home and alternate site infusion therapy in the U.S., with over 315,000 unique patients served in 2025 [4] - Financial performance for 2025 showed net revenue of $5.6 billion, a 13% increase from the previous year, despite headwinds from STELARA biosimilar adoption [7][11] Investment and Technology - Ongoing investments in automation and AI are aimed at improving patient administration tasks and expanding use cases beyond revenue cycle management [1] - The company has automated key processes, which supports operational efficiency and reduces reliance on human intervention [1] Provider and Payer Dynamics - Hospital systems are under economic pressure, leading to a focus on transitioning patients safely out of inpatient settings, with the company embedding registered nurses in these systems [2] - Payer interest in affordability initiatives is increasing, with the company expanding site-of-care programs to lower-cost settings [3] Financial Performance - The company reported a gross profit increase of 7.4% year-over-year, with adjusted EBITDA of $471 million, reflecting a margin of 8.3% [8] - Operating cash flow for 2025 was $258 million, below prior guidance due to strategic inventory purchases and increased working capital needs [8][9] Capital Allocation and Growth - The company invested in growth by adding over 80 infusion chairs and completed the acquisition of Intramed Plus, which exceeded expectations [10] - Share repurchase activities included over $300 million in shares during 2025, with an expanded authorization of $500 million [10] 2026 Outlook - The company reaffirmed its 2026 guidance, anticipating a revenue growth headwind of 400 basis points due to STELARA-related impacts [11] - Expected financial metrics for 2026 include revenue between $5.8 billion and $6.0 billion, adjusted EBITDA of $480 million to $505 million, and operating cash flow greater than $340 million [18] M&A Strategy - The company remains active in evaluating tuck-in acquisitions, emphasizing the need for strategic and financially attractive deals [15]